Aptamer Group Plc (DE:P0J)
FRANKFURT:P0J
P0J Stock Chart & Stats
€0.01
€0.00(0.00%)
At close: 4:00 PM EDT
€0.01
€0.00(0.00%)
Day’s Range― - ―
52-Week Range<€0.01 - €0.03
Previous CloseN/A
Volume0.00
Average Volume (3M)300.00
Market Cap
€21.97M
Enterprise Value€14.90M
Total Cash (Recent Filing)€1.53M
Total Debt (Recent Filing)€333.00K
Price to Earnings (P/E)―
Beta1.20
Next Earnings
Oct 20, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)<0.01
Shares Outstanding3,455,144,000
10 Day Avg. Volume300
30 Day Avg. Volume300
Financial Highlights & Ratios
PEG Ratio0.04
Price to Book (P/B)5.32
Price to Sales (P/S)6.11
P/FCF Ratio-3.66
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Proprietary Aptamer PlatformAptamer Group's core technology is a platform of synthetic oligonucleotide binders applicable across diagnostics, therapeutics and bioprocessing. A platform model provides durable leverage: single R&D advances can be reused across multiple product lines and customer segments over years.
Diversified End-market ApplicationsServing diagnostics, therapeutics and research/bioprocessing creates multiple long-term addressable markets. This structural diversification reduces reliance on any one commercialization path and increases chances of steady revenue sources as different markets mature at different rates.
Improved Leverage ManagementAn improving debt-to-equity ratio suggests management has reduced financial leverage or restructured obligations, strengthening balance sheet flexibility. Better leverage improves ability to raise non-dilutive capital and lengthens runway for R&D and commercialization efforts.
Bears Say
Severe Revenue DeclineA near-total revenue collapse is a structural red flag: it signals loss of commercial traction or contract terminations. Sustained low revenue constrains scale-up, reduces ability to invest in validation and commercialization, and makes financing more dilutive or costly over months.
Negative Operating And Free Cash FlowPersistent negative operating and free cash flows erode cash reserves and require external financing. Over a multi-month horizon this limits investment in product development, slows commercialization and can force equity issuance or asset sales that dilute long-term upside.
Poor Profitability And MarginsDeclining gross margins and negative net margins indicate the business isn't converting revenue to profit. Structurally weak margins reduce reinvestable cash, undermine returns on capital and hinder the firm's ability to fund long-term trials or scale manufacturing without outside capital.
Aptamer Group Plc News
P0J FAQ
What was Aptamer Group Plc’s price range in the past 12 months?
Aptamer Group Plc lowest stock price was <€0.01 and its highest was €0.03 in the past 12 months.
What is Aptamer Group Plc’s market cap?
Aptamer Group Plc’s market cap is €21.97M.
When is Aptamer Group Plc’s upcoming earnings report date?
Aptamer Group Plc’s upcoming earnings report date is Oct 20, 2026 which is in 136 days.
How were Aptamer Group Plc’s earnings last quarter?
Aptamer Group Plc released its earnings results on Mar 25, 2026. The company reported €0 earnings per share for the quarter, the consensus estimate of N/A by €0.
Is Aptamer Group Plc overvalued?
According to Wall Street analysts Aptamer Group Plc’s price is currently Overvalued.
Does Aptamer Group Plc pay dividends?
Aptamer Group Plc does not currently pay dividends.
What is Aptamer Group Plc’s EPS estimate?
Aptamer Group Plc’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Aptamer Group Plc have?
Aptamer Group Plc has 3,455,144,000 shares outstanding.
What happened to Aptamer Group Plc’s price movement after its last earnings report?
Aptamer Group Plc reported an EPS of €0 in its last earnings report, expectations of N/A. Following the earnings report the stock price went down -13.043%.
Which hedge fund is a major shareholder of Aptamer Group Plc?
Currently, no hedge funds are holding shares in DE:P0J
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Aptamer Group Plc
Aptamer Group plc provides binders for research, diagnostics, and therapeutics in the United Kingdom and internationally. The company's binders engineered to address issues which founds with molecules, such as antibodies; and offers solutions to bioprocessing, diagnostic, and pharmaceutical scientists. It serves pharma companies, diagnostic development companies, and research institutes. The company was incorporated in 2014 and is based in York, the United Kingdom.
Technical Analysis
Avacta Group plc
―
Bioventix
―
Oxford BioDynamics
―
Fusion Antibodies Plc
―
Arecor Therapeutics PLC
―
Options Prices
Currently, No data available
---